919 related articles for article (PubMed ID: 32345477)
1. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
[TBL] [Abstract][Full Text] [Related]
2. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
[TBL] [Abstract][Full Text] [Related]
3. Consistent Long-Term Therapy of Neovascular Age-Related Macular Degeneration Managed by 50 or More Anti-VEGF Injections Using a Treat-Extend-Stop Protocol.
Adrean SD; Chaili S; Ramkumar H; Pirouz A; Grant S
Ophthalmology; 2018 Jul; 125(7):1047-1053. PubMed ID: 29439828
[TBL] [Abstract][Full Text] [Related]
4. Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry.
Rao P; Lum F; Wood K; Salman C; Burugapalli B; Hall R; Singh S; Parke DW; Williams GA
Ophthalmology; 2018 Apr; 125(4):522-528. PubMed ID: 29146306
[TBL] [Abstract][Full Text] [Related]
5. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.
Brynskov T; Munch IC; Larsen TM; Erngaard L; Sørensen TL
Acta Ophthalmol; 2020 Mar; 98(2):132-138. PubMed ID: 31282617
[TBL] [Abstract][Full Text] [Related]
6. Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.
Lorés-Motta L; Riaz M; Grunin M; Corominas J; van Asten F; Pauper M; Leenders M; Richardson AJ; Muether P; Cree AJ; Griffiths HL; Pham C; Belanger MC; Meester-Smoor MA; Ali M; Heid IM; Fritsche LG; Chakravarthy U; Gale R; McKibbin M; Inglehearn CF; Schlingemann RO; Omar A; Chen J; Koenekoop RK; Fauser S; Guymer RH; Hoyng CB; de Jong EK; Lotery AJ; Mitchell P; den Hollander AI; Baird PN; Chowers I
JAMA Ophthalmol; 2018 Aug; 136(8):875-884. PubMed ID: 29852030
[TBL] [Abstract][Full Text] [Related]
7. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
[TBL] [Abstract][Full Text] [Related]
8. Worth changing? Clinical effects of switching treatment in neovascular age-related macular degeneration from intravitreal ranibizumab and aflibercept to bevacizumab in a region in southern Sweden.
Bro T; Hägg S
Eur J Ophthalmol; 2021 Jan; 31(1):144-148. PubMed ID: 31642333
[TBL] [Abstract][Full Text] [Related]
9. Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes.
Ciulla TA; Hussain RM; Pollack JS; Williams DF
Ophthalmol Retina; 2020 Jan; 4(1):19-30. PubMed ID: 31324588
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).
Daniel E; Shaffer J; Ying GS; Grunwald JE; Martin DF; Jaffe GJ; Maguire MG;
Ophthalmology; 2016 Mar; 123(3):609-16. PubMed ID: 26681392
[TBL] [Abstract][Full Text] [Related]
11. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
[TBL] [Abstract][Full Text] [Related]
12. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial.
Jackson TL; Soare C; Petrarca C; Simpson A; Neffendorf JE; Petrarca R; Muldrew A; Peto T; Chakravarthy U; Membrey L; Haynes R; Costen M; Steel D; Desai R;
JAMA Ophthalmol; 2020 Aug; 138(8):835-842. PubMed ID: 32644148
[TBL] [Abstract][Full Text] [Related]
14. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.
Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP
Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385
[TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
[TBL] [Abstract][Full Text] [Related]
16. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
17. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
[TBL] [Abstract][Full Text] [Related]
18. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
19. Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.
Gale RP; Pearce I; Eter N; Ghanchi F; Holz FG; Schmitz-Valckenberg S; Balaskas K; Burton BJL; Downes SM; Eleftheriadis H; George S; Gilmour D; Hamilton R; Lotery AJ; Patel N; Prakash P; Santiago C; Thomas S; Varma D; Walters G; Williams M; Wolf A; Zakri RH; Igwe F; Ayan F
Br J Ophthalmol; 2020 Apr; 104(4):493-499. PubMed ID: 31383649
[TBL] [Abstract][Full Text] [Related]
20. Macular Atrophy Affecting Visual Outcomes in Patients Undergoing Anti-VEGF Treatment in Routine Clinical Practice.
Rieveschl NB; Song W; Li A; Conti TF; Hom GL; Tsai GJ; Conti FF; Babiuch AS; Singh RP
Ophthalmic Surg Lasers Imaging Retina; 2020 Feb; 51(2):68-75. PubMed ID: 32084278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]